EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
This collaboration turns kitting into a strategic advantage for sponsors and sites
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Subscribe To Our Newsletter & Stay Updated